Oestrogen receptors β1 and βcx have divergent roles in breast cancer survival and lymph node metastasis

Background: The expression of oestrogen receptor (ER) α characterises a subset of breast cancers associated with good response to endocrine therapy. However, the clinical significance of the second ER, ER β 1, and its splice variant ER β cx is still unclear. Methods: We here report an assessment of...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of cancer Vol. 111; no. 5; pp. 918 - 926
Main Authors Rosin, G, de Boniface, J, Karthik, G M, Frisell, J, Bergh, J, Hartman, J
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 26.08.2014
Nature Publishing Group
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background: The expression of oestrogen receptor (ER) α characterises a subset of breast cancers associated with good response to endocrine therapy. However, the clinical significance of the second ER, ER β 1, and its splice variant ER β cx is still unclear. Methods: We here report an assessment of ER α , ER β 1 and ER β cx by immunohistochemistry using quantitative digital image analysis of 340 primary tumours and corresponding sentinel lymph nodes. Results: No differences were seen in ER levels in primary tumours vs lymph node metastases. ER β 1 and ER β cx were equally distributed among age groups and tumour histological grades. Loss of ER β 1 in the primary tumour was strongly associated with poor survival. Its prognostic impact was particularly evident in young patients and in high-grade tumours. The worst outcome was seen in the tumours lacking both ER α and ER β 1. ER β cx expression in the primary tumour correlated with a higher risk of lymph node metastasis, and with poor survival when expressed in sentinel node lymphocytes. Conclusions: Our study reveals highly significant although antagonising roles of ER β 1 and ER β cx in breast cancer. Consequently, we suggest that the histopathological assessment of ER β 1 is of value as a prognostic and potentially predictive biomarker.
AbstractList The expression of oestrogen receptor (ER) α characterises a subset of breast cancers associated with good response to endocrine therapy. However, the clinical significance of the second ER, ERβ1, and its splice variant ERβcx is still unclear.BACKGROUNDThe expression of oestrogen receptor (ER) α characterises a subset of breast cancers associated with good response to endocrine therapy. However, the clinical significance of the second ER, ERβ1, and its splice variant ERβcx is still unclear.We here report an assessment of ERα, ERβ1 and ERβcx by immunohistochemistry using quantitative digital image analysis of 340 primary tumours and corresponding sentinel lymph nodes.METHODSWe here report an assessment of ERα, ERβ1 and ERβcx by immunohistochemistry using quantitative digital image analysis of 340 primary tumours and corresponding sentinel lymph nodes.No differences were seen in ER levels in primary tumours vs lymph node metastases. ERβ1 and ERβcx were equally distributed among age groups and tumour histological grades. Loss of ERβ1 in the primary tumour was strongly associated with poor survival. Its prognostic impact was particularly evident in young patients and in high-grade tumours. The worst outcome was seen in the tumours lacking both ERα and ERβ1. ERβcx expression in the primary tumour correlated with a higher risk of lymph node metastasis, and with poor survival when expressed in sentinel node lymphocytes.RESULTSNo differences were seen in ER levels in primary tumours vs lymph node metastases. ERβ1 and ERβcx were equally distributed among age groups and tumour histological grades. Loss of ERβ1 in the primary tumour was strongly associated with poor survival. Its prognostic impact was particularly evident in young patients and in high-grade tumours. The worst outcome was seen in the tumours lacking both ERα and ERβ1. ERβcx expression in the primary tumour correlated with a higher risk of lymph node metastasis, and with poor survival when expressed in sentinel node lymphocytes.Our study reveals highly significant although antagonising roles of ERβ1 and ERβcx in breast cancer. Consequently, we suggest that the histopathological assessment of ERβ1 is of value as a prognostic and potentially predictive biomarker.CONCLUSIONSOur study reveals highly significant although antagonising roles of ERβ1 and ERβcx in breast cancer. Consequently, we suggest that the histopathological assessment of ERβ1 is of value as a prognostic and potentially predictive biomarker.
Background: The expression of oestrogen receptor (ER) α characterises a subset of breast cancers associated with good response to endocrine therapy. However, the clinical significance of the second ER, ER β 1, and its splice variant ER β cx is still unclear. Methods: We here report an assessment of ER α , ER β 1 and ER β cx by immunohistochemistry using quantitative digital image analysis of 340 primary tumours and corresponding sentinel lymph nodes. Results: No differences were seen in ER levels in primary tumours vs lymph node metastases. ER β 1 and ER β cx were equally distributed among age groups and tumour histological grades. Loss of ER β 1 in the primary tumour was strongly associated with poor survival. Its prognostic impact was particularly evident in young patients and in high-grade tumours. The worst outcome was seen in the tumours lacking both ER α and ER β 1. ER β cx expression in the primary tumour correlated with a higher risk of lymph node metastasis, and with poor survival when expressed in sentinel node lymphocytes. Conclusions: Our study reveals highly significant although antagonising roles of ER β 1 and ER β cx in breast cancer. Consequently, we suggest that the histopathological assessment of ER β 1 is of value as a prognostic and potentially predictive biomarker.
The expression of oestrogen receptor (ER) α characterises a subset of breast cancers associated with good response to endocrine therapy. However, the clinical significance of the second ER, ERβ1, and its splice variant ERβcx is still unclear. We here report an assessment of ERα, ERβ1 and ERβcx by immunohistochemistry using quantitative digital image analysis of 340 primary tumours and corresponding sentinel lymph nodes. No differences were seen in ER levels in primary tumours vs lymph node metastases. ERβ1 and ERβcx were equally distributed among age groups and tumour histological grades. Loss of ERβ1 in the primary tumour was strongly associated with poor survival. Its prognostic impact was particularly evident in young patients and in high-grade tumours. The worst outcome was seen in the tumours lacking both ERα and ERβ1. ERβcx expression in the primary tumour correlated with a higher risk of lymph node metastasis, and with poor survival when expressed in sentinel node lymphocytes. Our study reveals highly significant although antagonising roles of ERβ1 and ERβcx in breast cancer. Consequently, we suggest that the histopathological assessment of ERβ1 is of value as a prognostic and potentially predictive biomarker.
Author Bergh, J
Karthik, G M
Rosin, G
Frisell, J
de Boniface, J
Hartman, J
Author_xml – sequence: 1
  givenname: G
  surname: Rosin
  fullname: Rosin, G
  organization: Department of Oncology and Pathology, Karolinska Institutet, Department of Biosciences and Nutrition, Karolinska Institutet
– sequence: 2
  givenname: J
  surname: de Boniface
  fullname: de Boniface, J
  organization: Department of Molecular Medicine and Surgery, Karolinska Institutet, Department of Breast and Endocrine Surgery, Karolinska University Hospital
– sequence: 3
  givenname: G M
  surname: Karthik
  fullname: Karthik, G M
  organization: Department of Oncology and Pathology, Karolinska Institutet
– sequence: 4
  givenname: J
  surname: Frisell
  fullname: Frisell, J
  organization: Department of Molecular Medicine and Surgery, Karolinska Institutet, Department of Breast and Endocrine Surgery, Karolinska University Hospital
– sequence: 5
  givenname: J
  surname: Bergh
  fullname: Bergh, J
  organization: Department of Oncology and Pathology, Karolinska Institutet, Radiumhemmet, Karolinska Oncology, Karolinska University Hospital
– sequence: 6
  givenname: J
  surname: Hartman
  fullname: Hartman, J
  email: johan.hartman@ki.se
  organization: Department of Oncology and Pathology, Karolinska Institutet, Department of Clinical Pathology, Karolinska University Hospital
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28772472$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/25025959$$D View this record in MEDLINE/PubMed
http://kipublications.ki.se/Default.aspx?queryparsed=id:129681837$$DView record from Swedish Publication Index
BookMark eNp1kstu1DAUhi3Uik4LO9bIGyQWZPAlnjgbpKriUqlSN7C2PM7JjIfEHuwk0NfiQXgmzjDTG4KVL-c7_7mekqMQAxDygrM5Z1K_XW7cXDBezmWtn5AZV1IUXIvqiMwYY1XBasFOyGnOG3zWTFdPyYlQTKha1TPiryEPKa4g0AQOtkNMmf76yakNDZ7uB13bCWjjJ0gIDTTFDjL1gS4T2DxQZ4ODRPOYJj_Z7o9fd9Nv1zTEBmgPA1I2-_yMHLe2y_D8cJ6RLx_ef774VFxdf7y8OL8qXCm1LsCVjS0XrVZOSWeVFbXCmkpXtkxVSmkJDbQggcGSuXbBF9K1gtfcWtlwzuUZKfa6-Ttsx6XZJt_bdGOi9ebw9RVvYJRgotLIv9vzaOmhcVhkst0jt8eW4NdmFSdTcuyilijw-iCQ4rcR22l6nx10nQ0Qx2w4Jq0Er_Qut5cPY90FuZ0HAq8OgM3Odm3C7vp8z-mqEmUlkHuz51yKOSdo7xDOzG4tDK6F2a2FwbVAXPyFOz_YwcddRb77n9NtI1E7rCCZTRxTwNn9m_8NvYnNtQ
CODEN BJCAAI
CitedBy_id crossref_primary_10_1530_JME_16_0082
crossref_primary_10_1186_s13046_017_0545_x
crossref_primary_10_31618_ESU_2413_9335_2020_1_77_959
crossref_primary_10_1016_j_canlet_2014_12_022
crossref_primary_10_1016_j_canlet_2015_07_017
crossref_primary_10_1016_j_pharmthera_2023_108350
crossref_primary_10_3389_fendo_2018_00781
crossref_primary_10_1111_iep_12266
crossref_primary_10_3390_ijms22041656
crossref_primary_10_1080_10428194_2016_1193853
crossref_primary_10_3389_fcell_2023_1240386
crossref_primary_10_1093_jnci_djw236
crossref_primary_10_4252_wjsc_v11_i9_594
crossref_primary_10_4137_GEG_S35500
crossref_primary_10_18632_oncotarget_10871
crossref_primary_10_1016_j_ejmech_2024_116896
crossref_primary_10_1016_j_trecan_2015_12_001
crossref_primary_10_1016_j_maturitas_2016_11_005
Cites_doi 10.1186/1471-2164-7-127
10.1007/s10549-006-9229-5
10.1158/0008-5472.CAN-06-0017
10.1158/1078-0432.CCR-07-4528
10.1002/1097-0142(19831101)52:9<1551::AID-CNCR2820520902>3.0.CO;2-3
10.1038/modpathol.2009.158
10.1200/JCO.2007.14.2968
10.1158/1078-0432.CCR-06-1823
10.1136/jcp.55.5.371
10.1210/en.2006-0563
10.1007/s10549-004-4262-8
10.1200/JCO.1999.17.5.1474
10.1002/path.1077
10.1186/1746-1596-6-6
10.1007/s13277-010-0144-3
10.1002/bjs.7820
10.1016/S0959-8049(01)00383-5
10.1158/0008-5472.CAN-06-3505
10.1073/pnas.0308319100
10.1093/aje/kwk052
10.1073/pnas.93.12.5925
10.2119/molmed.2010.00172
10.1038/nature10730
10.1200/JCO.2009.24.5001
10.1186/1471-2407-12-79
10.1210/endo.139.10.6216
10.1016/j.steroids.2009.02.005
10.1002/ijc.22892
10.1002/path.1883
10.1186/bcr2139
10.1016/S0140-6736(11)60993-8
10.1093/nar/26.15.3505
10.1136/jcp.2006.040378
10.1053/hupa.2001.21506
ContentType Journal Article
Copyright The Author(s) 2014
2015 INIST-CNRS
Copyright © 2014 Cancer Research UK 2014 Cancer Research UK
Copyright_xml – notice: The Author(s) 2014
– notice: 2015 INIST-CNRS
– notice: Copyright © 2014 Cancer Research UK 2014 Cancer Research UK
DBID C6C
AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ADTPV
AOWAS
D8T
ZZAVC
DOI 10.1038/bjc.2014.398
DatabaseName Springer Nature OA Free Journals
CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
SwePub
SwePub Articles
SWEPUB Freely available online
SwePub Articles full text
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate ERβ and βcx affect breast cancer prognosis
EISSN 1532-1827
EndPage 926
ExternalDocumentID oai_swepub_ki_se_520278
PMC4150283
25025959
28772472
10_1038_bjc_2014_398
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-Q-
0R~
23N
36B
39C
3V.
4.4
406
53G
5GY
5RE
6J9
70F
7RV
7X7
88E
8AO
8C1
8FI
8FJ
8R4
8R5
AANZL
AAWTL
AAYZH
AAZLF
ABAKF
ABAWZ
ABDBF
ABLJU
ABOCM
ABUWG
ABZZP
ACAOD
ACGFO
ACGFS
ACKTT
ACPRK
ACRQY
ACUHS
ACZOJ
ADBBV
ADFRT
ADHDB
AEFQL
AEJRE
AEMSY
AENEX
AEVLU
AFBBN
AFKRA
AFRAH
AFSHS
AGAYW
AGHAI
AGQEE
AHMBA
AHSBF
AILAN
AJRNO
ALFFA
ALMA_UNASSIGNED_HOLDINGS
AMYLF
AN0
AOIJS
ASPBG
AVWKF
AXYYD
AZFZN
B0M
BAWUL
BBNVY
BENPR
BHPHI
BKEYQ
BKKNO
BNQBC
BPHCQ
BVXVI
C6C
CCPQU
CS3
DIK
DNIVK
DPUIP
DU5
E3Z
EAD
EAP
EAS
EBC
EBD
EBLON
EBS
EE.
EIOEI
EJD
EMB
EMK
EMOBN
EPL
ESX
EX3
F5P
FDQFY
FEDTE
FERAY
FIZPM
FRJ
FSGXE
FYUFA
GX1
HCIFZ
HMCUK
HVGLF
HYE
HZ~
IH2
IWAJR
JSO
JZLTJ
KQ8
M1P
M7P
NAO
NAPCQ
NQJWS
O9-
OK1
P2P
PQQKQ
PROAC
PSQYO
Q2X
RNT
RNTTT
ROL
RPM
SNX
SNYQT
SOHCF
SOJ
SRMVM
SV3
SWTZT
TAOOD
TBHMF
TDRGL
TR2
TUS
UKHRP
W2D
WH7
WOW
~02
~8M
AAFWJ
AASML
AAYXX
ABBRH
ABDBE
ABFSG
ACMFV
ACSTC
AEZWR
AFDZB
AFHIU
AHWEU
AIGIU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
.55
.GJ
8WZ
A6W
AACDK
AATNV
AEXYK
AI.
CAG
COF
FIGPU
IQODW
J5H
M41
UDS
VH1
X7M
Y6R
ZGI
CGR
CUY
CVF
ECM
EIF
NPM
7X8
PPXIY
PQGLB
5PM
ABRTQ
PJZUB
ADTPV
AOWAS
D8T
PUEGO
ZZAVC
ID FETCH-LOGICAL-c4388-ec4da46f85c53ca5a2951534c4f0575583edefe3e0eb0cf6163cf2191aa3d1113
IEDL.DBID C6C
ISSN 0007-0920
1532-1827
IngestDate Mon Aug 25 03:38:47 EDT 2025
Thu Aug 21 18:17:49 EDT 2025
Fri Jul 11 00:14:34 EDT 2025
Wed Feb 19 02:15:40 EST 2025
Wed Apr 02 07:25:10 EDT 2025
Thu Apr 24 22:52:30 EDT 2025
Tue Jul 01 01:29:38 EDT 2025
Fri Feb 21 02:39:47 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords breast cancer
pathology
oestrogen receptor
biomarkers
oncology
endocrine therapy
Estrogen receptor
Breast disease
Hormone therapy
Estrogen
Biological marker
Malignant lymphadenopathy
Malignant hemopathy
Breast cancer
Malignant tumor
Survival
Ovarian hormone
Lymph node metastasis
Mammary gland diseases
Anatomic pathology
Cancerology
Sex steroid hormone
Cancer
Hormonal receptor
Language English
License CC BY 4.0
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4388-ec4da46f85c53ca5a2951534c4f0575583edefe3e0eb0cf6163cf2191aa3d1113
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.nature.com/articles/bjc.2014.398
PMID 25025959
PQID 1558521781
PQPubID 23479
PageCount 9
ParticipantIDs swepub_primary_oai_swepub_ki_se_520278
pubmedcentral_primary_oai_pubmedcentral_nih_gov_4150283
proquest_miscellaneous_1558521781
pubmed_primary_25025959
pascalfrancis_primary_28772472
crossref_primary_10_1038_bjc_2014_398
crossref_citationtrail_10_1038_bjc_2014_398
springer_journals_10_1038_bjc_2014_398
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20140826
PublicationDateYYYYMMDD 2014-08-26
PublicationDate_xml – month: 8
  year: 2014
  text: 20140826
  day: 26
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
– name: Basingstoke
– name: England
PublicationTitle British journal of cancer
PublicationTitleAbbrev Br J Cancer
PublicationTitleAlternate Br J Cancer
PublicationYear 2014
Publisher Nature Publishing Group UK
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
References Harvey, Clark, Osborne, Allred (CR14) 1999; 17
Honma, Horii, Iwase, Saji, Younes, Takubo, Matsuura, Ito, Akiyama, Sakamoto (CR16) 2008; 26
Kuiper, Lemmen, Carlsson, Corton, Safe, van der Saag, van der Burg, Gustafsson (CR19) 1998; 139
Fisher, Bauer, Wickerham, Redmond, Fisher, Cruz, Foster, Gardner, Lerner, Margolese (CR8) 1983; 52
Weitsman, Skliris, Ung, Peng, Younes, Watson, Murphy (CR35) 2006; 100
Andersson, Frisell, Sylvan, de Boniface, Bergkvist (CR2) 2010; 28
Gruvberger-Saal, Bendahl, Saal, Laakso, Hegardt, Eden, Peterson, Malmstrom, Isola, Borg, Fernö (CR10) 2007; 13
Gschwantler-Kaulich, Fink-Retter, Czerwenka, Hudelist, Kaulich, Kubista, Singer (CR11) 2011; 32
Zhao, Matthews, Tujague, Wan, Strom, Toresson, Lam, Cheng, Gustafsson, Dahlman-Wright (CR36) 2007; 67
Andersson, de Boniface, Jönsson, Ingvar, Liljegren, Bergkvist, Frisell (CR1) 2012; 99
Krecsák, Micsik, Kiszler, Krenács, Szabó, Jónás, Császár, Czuni, Gurzó, Ficsor, Molnár (CR17) 2011; 6
Hartman, Lindberg, Morani, Inzunza, Ström, Gustafsson (CR12) 2006; 66
Hartman, Ström, Gustafsson (CR13) 2009; 74
Ström, Hartman, Foster, Kietz, Wimalasena, Gustafsson (CR33) 2004; 101
Shim, Gherman, Kim, Omoto, Iwase, Bouton, Kis, Andersson, Warner, Gustafsson (CR29) 2006; 208
Sorlie, Wang, Xiao, Johnsen, Naume, Samaha, Børresen-Dale (CR31) 2006; 7
Chang, Frasor, Komm, Katzenellenbogen (CR6) 2006; 147
Rosin, Hannelius, Lindström, Hall, Bergh, Hartman, Kere (CR26) 2012; 12
Hill, Jeganathan, Chinnasamy, Grimaldi, Diamond (CR15) 2011; 17
Skliris, Parkes, Limer, Burdall, Carder, Speirs (CR30) 2002; 197
Speirs, Skliris, Burdall, Carder (CR32) 2002; 55
Roger, Sahla, Mäkelä, Gustafsson, Baldet, Rochefort (CR25) 2001; 61
Shaaban, Green, Karthik, Alizadeh, Hughes, Harkins, Ellis, Robertson, Paish, Saunders, Groome, Speirs (CR28) 2008; 14
Bentzon, Düring, Rasmussen, Mouridsen, Kroman (CR3) 2008; 122
Carder, Murphy, Dervan, Kennedy, McCann, Saunders, Shaaban, Foster, Witton, Bartlett, Walker, Speirs (CR5) 2005; 92
Kuiper, Enmark, Pelto-Huikko, Nilsson, Gustafsson (CR18) 1996; 93
Vittinghoff, McCulloch (CR34) 2007; 165
Mann, Laucirica, Carlson, Younes, Ali, Younes, Li, Younes (CR20) 2001; 32
Ogawa, Inoue, Watanabe, Orimo, Hosoi, Ouchi, Muramatsu (CR23) 1998; 26
Davies, Godwin, Gray, Clarke, Cutter, Darby, McGale, Pan, Taylor, Wang, Dowsett, Ingle, Peto (CR7) 2011; 378
Marotti, Collins, Hu, Tamimi (CR21) 2009; 23
Fuqua, Schiff, Parra, Moore, Mohsin, Osborne, Clark, Allred (CR9) 2003; 63
Ross-Innes, Stark, Teschendorff, Holmes, Ali, Dunning, Brown, Gojis, Ellis, Green, Ali, Chin, Palmieri, Caldas, Carroll (CR27) 2012; 481
Borgquist, Holm, Stendahl, Anagnostaki, Landberg, Jirström (CR4) 2008; 61
Novelli, Milella, Melucci, Di Benedetto, Sperduti, Perrone-Donnorso, Perracchio, Venturo, Nisticò, Fabi, Buglioni, Natali, Mottolese (CR22) 2008; 10
Omoto, Kobayashi, Inoue, Ogawa, Toyama, Yamashita, Muramatsu, Gustafsson, Iwase (CR24) 2002; 38
GE Weitsman (BFbjc2014398_CR35) 2006; 100
F Novelli (BFbjc2014398_CR22) 2008; 10
S Ogawa (BFbjc2014398_CR23) 1998; 26
P Roger (BFbjc2014398_CR25) 2001; 61
S Borgquist (BFbjc2014398_CR4) 2008; 61
SAW Fuqua (BFbjc2014398_CR9) 2003; 63
C Davies (BFbjc2014398_CR7) 2011; 378
GP Skliris (BFbjc2014398_CR30) 2002; 197
D Gschwantler-Kaulich (BFbjc2014398_CR11) 2011; 32
J Hartman (BFbjc2014398_CR13) 2009; 74
E Vittinghoff (BFbjc2014398_CR34) 2007; 165
JM Harvey (BFbjc2014398_CR14) 1999; 17
GG Kuiper (BFbjc2014398_CR18) 1996; 93
C Zhao (BFbjc2014398_CR36) 2007; 67
N Bentzon (BFbjc2014398_CR3) 2008; 122
V Speirs (BFbjc2014398_CR32) 2002; 55
T Sorlie (BFbjc2014398_CR31) 2006; 7
PJ Carder (BFbjc2014398_CR5) 2005; 92
L Hill (BFbjc2014398_CR15) 2011; 17
Y Omoto (BFbjc2014398_CR24) 2002; 38
AM Shaaban (BFbjc2014398_CR28) 2008; 14
J Hartman (BFbjc2014398_CR12) 2006; 66
A Ström (BFbjc2014398_CR33) 2004; 101
SK Gruvberger-Saal (BFbjc2014398_CR10) 2007; 13
S Mann (BFbjc2014398_CR20) 2001; 32
CS Ross-Innes (BFbjc2014398_CR27) 2012; 481
Y Andersson (BFbjc2014398_CR2) 2010; 28
G-J Shim (BFbjc2014398_CR29) 2006; 208
JD Marotti (BFbjc2014398_CR21) 2009; 23
G Rosin (BFbjc2014398_CR26) 2012; 12
B Fisher (BFbjc2014398_CR8) 1983; 52
GG Kuiper (BFbjc2014398_CR19) 1998; 139
EC Chang (BFbjc2014398_CR6) 2006; 147
L Krecsák (BFbjc2014398_CR17) 2011; 6
Y Andersson (BFbjc2014398_CR1) 2012; 99
N Honma (BFbjc2014398_CR16) 2008; 26
11818203 - Eur J Cancer. 2002 Feb;38(3):380-6
22375924 - BMC Cancer. 2012;12:79
11986344 - J Clin Pathol. 2002 May;55(5):371-4
9671811 - Nucleic Acids Res. 1998 Aug 1;26(15):3505-12
18771580 - Breast Cancer Res. 2008;10(5):R74
12015738 - J Pathol. 2002 Jun;197(2):155-62
17145865 - Cancer Res. 2006 Dec 1;66(23):11207-13
17440111 - Cancer Res. 2007 Apr 15;67(8):3955-62
18223096 - J Clin Pathol. 2008 Feb;61(2):197-203
18669459 - J Clin Oncol. 2008 Aug 1;26(22):3727-34
11289127 - Cancer Res. 2001 Mar 15;61(6):2537-41
16729877 - BMC Genomics. 2006;7:127
10334533 - J Clin Oncol. 1999 May;17(5):1474-81
6352003 - Cancer. 1983 Nov 1;52(9):1551-7
21244664 - Diagn Pathol. 2011;6:6
12750263 - Cancer Res. 2003 May 15;63(10):2434-9
22217937 - Nature. 2012 Jan 19;481(7381):389-93
19463683 - Steroids. 2009 Aug;74(8):635-41
17404078 - Clin Cancer Res. 2007 Apr 1;13(7):1987-94
21188569 - Tumour Biol. 2011 Jun;32(3):501-8
17960621 - Int J Cancer. 2008 Mar 1;122(5):1089-94
16705367 - Breast Cancer Res Treat. 2006 Nov;100(1):23-31
22180063 - Br J Surg. 2012 Feb;99(2):226-31
17182981 - Am J Epidemiol. 2007 Mar 15;165(6):710-8
18698041 - Clin Cancer Res. 2008 Aug 15;14(16):5228-35
20458033 - J Clin Oncol. 2010 Jun 10;28(17):2868-73
14745018 - Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1566-71
8650195 - Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5925-30
19898422 - Mod Pathol. 2010 Feb;23(2):197-204
16155800 - Breast Cancer Res Treat. 2005 Aug;92(3):287-93
9751507 - Endocrinology. 1998 Oct;139(10):4252-63
21107497 - Mol Med. 2011 Mar-Apr;17(3-4):211-20
21802721 - Lancet. 2011 Aug 27;378(9793):771-84
11172304 - Hum Pathol. 2001 Jan;32(1):113-8
16809442 - Endocrinology. 2006 Oct;147(10):4831-42
16294372 - J Pathol. 2006 Feb;208(3):408-14
References_xml – volume: 7
  start-page: 127
  year: 2006
  ident: CR31
  article-title: Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms
  publication-title: BMC Genomics
  doi: 10.1186/1471-2164-7-127
– volume: 100
  start-page: 23
  year: 2006
  end-page: 31
  ident: CR35
  article-title: Assessment of multiple different estrogen receptor-beta antibodies for their ability to immunoprecipitate under chromatin immunoprecipitation conditions
  publication-title: Breast Cancer Res
  doi: 10.1007/s10549-006-9229-5
– volume: 66
  start-page: 11207
  year: 2006
  end-page: 11213
  ident: CR12
  article-title: Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-06-0017
– volume: 14
  start-page: 5228
  year: 2008
  end-page: 5235
  ident: CR28
  article-title: Nuclear and cytoplasmic expression of ER 1, ER 2, and ER 5 identifies distinct prognostic outcome for breast cancer patients
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-07-4528
– volume: 52
  start-page: 1551
  year: 1983
  end-page: 1557
  ident: CR8
  article-title: Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. an NSABP update
  publication-title: Cancer
  doi: 10.1002/1097-0142(19831101)52:9<1551::AID-CNCR2820520902>3.0.CO;2-3
– volume: 23
  start-page: 197
  year: 2009
  end-page: 204
  ident: CR21
  article-title: Estrogen receptor
  publication-title: Mod Pathol
  doi: 10.1038/modpathol.2009.158
– volume: 26
  start-page: 3727
  year: 2008
  end-page: 3734
  ident: CR16
  article-title: Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2007.14.2968
– volume: 13
  start-page: 1987
  year: 2007
  end-page: 1994
  ident: CR10
  article-title: Estrogen receptor expression is associated with tamoxifen response in ER-negative breast carcinoma
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-06-1823
– volume: 55
  start-page: 371
  year: 2002
  end-page: 374
  ident: CR32
  article-title: Distinct expression patterns of ER alpha and ER beta in normal human mammary gland
  publication-title: J Clin Pathol
  doi: 10.1136/jcp.55.5.371
– volume: 147
  start-page: 4831
  year: 2006
  end-page: 4842
  ident: CR6
  article-title: Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells
  publication-title: Endocrinology
  doi: 10.1210/en.2006-0563
– volume: 92
  start-page: 287
  year: 2005
  end-page: 293
  ident: CR5
  article-title: A multi-centre investigation towards reaching a consensus on the immunohistochemical detection of ERβ in archival formalin-fixed paraffin embedded human breast tissue
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-004-4262-8
– volume: 63
  start-page: 2434
  year: 2003
  end-page: 2439
  ident: CR9
  article-title: Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters
  publication-title: Cancer Res
– volume: 17
  start-page: 1474
  year: 1999
  end-page: 1481
  ident: CR14
  article-title: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.1999.17.5.1474
– volume: 197
  start-page: 155
  year: 2002
  end-page: 162
  ident: CR30
  article-title: Evaluation of seven oestrogen receptor beta antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue
  publication-title: J Pathol
  doi: 10.1002/path.1077
– volume: 6
  start-page: 6
  year: 2011
  ident: CR17
  article-title: Technical note on the validation of a semi-automated image analysis software application for estrogen and progesterone receptor detection in breast cancer
  publication-title: Diagn Pathol
  doi: 10.1186/1746-1596-6-6
– volume: 32
  start-page: 501
  year: 2011
  end-page: 508
  ident: CR11
  article-title: Differential expression pattern of estrogen receptors, aromatase, and sulfotransferase in breast cancer tissue and corresponding lymph node metastases
  publication-title: Tumour Biol
  doi: 10.1007/s13277-010-0144-3
– volume: 99
  start-page: 226
  year: 2012
  end-page: 231
  ident: CR1
  article-title: Axillary recurrence rate 5 years after negative sentinel node biopsy for breast cancer
  publication-title: Br J Surg
  doi: 10.1002/bjs.7820
– volume: 38
  start-page: 380
  year: 2002
  end-page: 386
  ident: CR24
  article-title: Evaluation of oestrogen receptor beta wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancers
  publication-title: Eur J Cancer
  doi: 10.1016/S0959-8049(01)00383-5
– volume: 67
  start-page: 3955
  year: 2007
  end-page: 3962
  ident: CR36
  article-title: Estrogen receptor beta2 negatively regulates the transactivation of estrogen receptor alpha in human breast cancer cells
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-06-3505
– volume: 101
  start-page: 1566
  year: 2004
  end-page: 1571
  ident: CR33
  article-title: Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0308319100
– volume: 165
  start-page: 710
  year: 2007
  end-page: 718
  ident: CR34
  article-title: Relaxing the rule of ten events per variable in logistic and Cox regression
  publication-title: Am J Epidemiol
  doi: 10.1093/aje/kwk052
– volume: 93
  start-page: 5925
  year: 1996
  end-page: 5930
  ident: CR18
  article-title: Cloning of a novel receptor expressed in rat prostate and ovary
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.93.12.5925
– volume: 17
  start-page: 211
  year: 2011
  end-page: 220
  ident: CR15
  article-title: Differential roles of estrogen receptors α and β in control of B-cell maturation and selection
  publication-title: Mol Med
  doi: 10.2119/molmed.2010.00172
– volume: 481
  start-page: 389
  year: 2012
  end-page: 393
  ident: CR27
  article-title: Differential oestrogen receptor binding is associated with clinical outcome in breast cancer
  publication-title: Nature
  doi: 10.1038/nature10730
– volume: 28
  start-page: 2868
  year: 2010
  end-page: 2873
  ident: CR2
  article-title: Breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.24.5001
– volume: 12
  start-page: 79
  year: 2012
  ident: CR26
  article-title: The dyslexia candidate gene DYX1C1 is a potential marker of poor survival in breast cancer
  publication-title: BMC Cancer
  doi: 10.1186/1471-2407-12-79
– volume: 139
  start-page: 4252
  year: 1998
  end-page: 4263
  ident: CR19
  article-title: Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta
  publication-title: Endocrinology
  doi: 10.1210/endo.139.10.6216
– volume: 74
  start-page: 635
  year: 2009
  end-page: 641
  ident: CR13
  article-title: Estrogen receptor beta in breast cancer—diagnostic and therapeutic implications
  publication-title: Steroids
  doi: 10.1016/j.steroids.2009.02.005
– volume: 122
  start-page: 1089
  year: 2008
  end-page: 1094
  ident: CR3
  article-title: Prognostic effect of estrogen receptor status across age in primary breast cancer
  publication-title: Int J Cancer
  doi: 10.1002/ijc.22892
– volume: 208
  start-page: 408
  year: 2006
  end-page: 414
  ident: CR29
  article-title: Differential expression of oestrogen receptors in human secondary lymphoid tissues
  publication-title: J Pathol
  doi: 10.1002/path.1883
– volume: 61
  start-page: 2537
  year: 2001
  end-page: 2541
  ident: CR25
  article-title: Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors
  publication-title: Cancer Res
– volume: 10
  start-page: R74
  year: 2008
  ident: CR22
  article-title: A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study
  publication-title: Breast Cancer Res
  doi: 10.1186/bcr2139
– volume: 378
  start-page: 771
  year: 2011
  end-page: 784
  ident: CR7
  article-title: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
  publication-title: Lancet
  doi: 10.1016/S0140-6736(11)60993-8
– volume: 26
  start-page: 3505
  year: 1998
  end-page: 3512
  ident: CR23
  article-title: Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor ofestrogen action in human
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/26.15.3505
– volume: 61
  start-page: 197
  year: 2008
  end-page: 203
  ident: CR4
  article-title: Oestrogen receptors alpha and beta show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer
  publication-title: J Clin Pathol
  doi: 10.1136/jcp.2006.040378
– volume: 32
  start-page: 113
  year: 2001
  end-page: 118
  ident: CR20
  article-title: Estrogen receptor beta expression in invasive breast cancer
  publication-title: Hum Pathol
  doi: 10.1053/hupa.2001.21506
– volume: 17
  start-page: 1474
  year: 1999
  ident: BFbjc2014398_CR14
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.1999.17.5.1474
– volume: 17
  start-page: 211
  year: 2011
  ident: BFbjc2014398_CR15
  publication-title: Mol Med
  doi: 10.2119/molmed.2010.00172
– volume: 92
  start-page: 287
  year: 2005
  ident: BFbjc2014398_CR5
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-004-4262-8
– volume: 26
  start-page: 3505
  year: 1998
  ident: BFbjc2014398_CR23
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/26.15.3505
– volume: 165
  start-page: 710
  year: 2007
  ident: BFbjc2014398_CR34
  publication-title: Am J Epidemiol
  doi: 10.1093/aje/kwk052
– volume: 67
  start-page: 3955
  year: 2007
  ident: BFbjc2014398_CR36
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-06-3505
– volume: 61
  start-page: 2537
  year: 2001
  ident: BFbjc2014398_CR25
  publication-title: Cancer Res
– volume: 14
  start-page: 5228
  year: 2008
  ident: BFbjc2014398_CR28
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-07-4528
– volume: 139
  start-page: 4252
  year: 1998
  ident: BFbjc2014398_CR19
  publication-title: Endocrinology
  doi: 10.1210/endo.139.10.6216
– volume: 99
  start-page: 226
  year: 2012
  ident: BFbjc2014398_CR1
  publication-title: Br J Surg
  doi: 10.1002/bjs.7820
– volume: 26
  start-page: 3727
  year: 2008
  ident: BFbjc2014398_CR16
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2007.14.2968
– volume: 63
  start-page: 2434
  year: 2003
  ident: BFbjc2014398_CR9
  publication-title: Cancer Res
– volume: 6
  start-page: 6
  year: 2011
  ident: BFbjc2014398_CR17
  publication-title: Diagn Pathol
  doi: 10.1186/1746-1596-6-6
– volume: 13
  start-page: 1987
  year: 2007
  ident: BFbjc2014398_CR10
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-06-1823
– volume: 197
  start-page: 155
  year: 2002
  ident: BFbjc2014398_CR30
  publication-title: J Pathol
  doi: 10.1002/path.1077
– volume: 122
  start-page: 1089
  year: 2008
  ident: BFbjc2014398_CR3
  publication-title: Int J Cancer
  doi: 10.1002/ijc.22892
– volume: 481
  start-page: 389
  year: 2012
  ident: BFbjc2014398_CR27
  publication-title: Nature
  doi: 10.1038/nature10730
– volume: 55
  start-page: 371
  year: 2002
  ident: BFbjc2014398_CR32
  publication-title: J Clin Pathol
  doi: 10.1136/jcp.55.5.371
– volume: 74
  start-page: 635
  year: 2009
  ident: BFbjc2014398_CR13
  publication-title: Steroids
  doi: 10.1016/j.steroids.2009.02.005
– volume: 23
  start-page: 197
  year: 2009
  ident: BFbjc2014398_CR21
  publication-title: Mod Pathol
  doi: 10.1038/modpathol.2009.158
– volume: 100
  start-page: 23
  year: 2006
  ident: BFbjc2014398_CR35
  publication-title: Breast Cancer Res
  doi: 10.1007/s10549-006-9229-5
– volume: 32
  start-page: 501
  year: 2011
  ident: BFbjc2014398_CR11
  publication-title: Tumour Biol
  doi: 10.1007/s13277-010-0144-3
– volume: 10
  start-page: R74
  year: 2008
  ident: BFbjc2014398_CR22
  publication-title: Breast Cancer Res
  doi: 10.1186/bcr2139
– volume: 208
  start-page: 408
  year: 2006
  ident: BFbjc2014398_CR29
  publication-title: J Pathol
  doi: 10.1002/path.1883
– volume: 61
  start-page: 197
  year: 2008
  ident: BFbjc2014398_CR4
  publication-title: J Clin Pathol
  doi: 10.1136/jcp.2006.040378
– volume: 66
  start-page: 11207
  year: 2006
  ident: BFbjc2014398_CR12
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-06-0017
– volume: 28
  start-page: 2868
  year: 2010
  ident: BFbjc2014398_CR2
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.24.5001
– volume: 32
  start-page: 113
  year: 2001
  ident: BFbjc2014398_CR20
  publication-title: Hum Pathol
  doi: 10.1053/hupa.2001.21506
– volume: 12
  start-page: 79
  year: 2012
  ident: BFbjc2014398_CR26
  publication-title: BMC Cancer
  doi: 10.1186/1471-2407-12-79
– volume: 147
  start-page: 4831
  year: 2006
  ident: BFbjc2014398_CR6
  publication-title: Endocrinology
  doi: 10.1210/en.2006-0563
– volume: 101
  start-page: 1566
  year: 2004
  ident: BFbjc2014398_CR33
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0308319100
– volume: 52
  start-page: 1551
  year: 1983
  ident: BFbjc2014398_CR8
  publication-title: Cancer
  doi: 10.1002/1097-0142(19831101)52:9<1551::AID-CNCR2820520902>3.0.CO;2-3
– volume: 38
  start-page: 380
  year: 2002
  ident: BFbjc2014398_CR24
  publication-title: Eur J Cancer
  doi: 10.1016/S0959-8049(01)00383-5
– volume: 7
  start-page: 127
  year: 2006
  ident: BFbjc2014398_CR31
  publication-title: BMC Genomics
  doi: 10.1186/1471-2164-7-127
– volume: 378
  start-page: 771
  year: 2011
  ident: BFbjc2014398_CR7
  publication-title: Lancet
  doi: 10.1016/S0140-6736(11)60993-8
– volume: 93
  start-page: 5925
  year: 1996
  ident: BFbjc2014398_CR18
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.93.12.5925
– reference: 17440111 - Cancer Res. 2007 Apr 15;67(8):3955-62
– reference: 12015738 - J Pathol. 2002 Jun;197(2):155-62
– reference: 21107497 - Mol Med. 2011 Mar-Apr;17(3-4):211-20
– reference: 9751507 - Endocrinology. 1998 Oct;139(10):4252-63
– reference: 19463683 - Steroids. 2009 Aug;74(8):635-41
– reference: 19898422 - Mod Pathol. 2010 Feb;23(2):197-204
– reference: 11172304 - Hum Pathol. 2001 Jan;32(1):113-8
– reference: 16705367 - Breast Cancer Res Treat. 2006 Nov;100(1):23-31
– reference: 14745018 - Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1566-71
– reference: 20458033 - J Clin Oncol. 2010 Jun 10;28(17):2868-73
– reference: 6352003 - Cancer. 1983 Nov 1;52(9):1551-7
– reference: 22375924 - BMC Cancer. 2012;12:79
– reference: 22180063 - Br J Surg. 2012 Feb;99(2):226-31
– reference: 21188569 - Tumour Biol. 2011 Jun;32(3):501-8
– reference: 16294372 - J Pathol. 2006 Feb;208(3):408-14
– reference: 17182981 - Am J Epidemiol. 2007 Mar 15;165(6):710-8
– reference: 21244664 - Diagn Pathol. 2011;6:6
– reference: 17404078 - Clin Cancer Res. 2007 Apr 1;13(7):1987-94
– reference: 10334533 - J Clin Oncol. 1999 May;17(5):1474-81
– reference: 18669459 - J Clin Oncol. 2008 Aug 1;26(22):3727-34
– reference: 17960621 - Int J Cancer. 2008 Mar 1;122(5):1089-94
– reference: 11986344 - J Clin Pathol. 2002 May;55(5):371-4
– reference: 12750263 - Cancer Res. 2003 May 15;63(10):2434-9
– reference: 17145865 - Cancer Res. 2006 Dec 1;66(23):11207-13
– reference: 8650195 - Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5925-30
– reference: 18771580 - Breast Cancer Res. 2008;10(5):R74
– reference: 16155800 - Breast Cancer Res Treat. 2005 Aug;92(3):287-93
– reference: 18223096 - J Clin Pathol. 2008 Feb;61(2):197-203
– reference: 18698041 - Clin Cancer Res. 2008 Aug 15;14(16):5228-35
– reference: 21802721 - Lancet. 2011 Aug 27;378(9793):771-84
– reference: 11289127 - Cancer Res. 2001 Mar 15;61(6):2537-41
– reference: 16729877 - BMC Genomics. 2006;7:127
– reference: 9671811 - Nucleic Acids Res. 1998 Aug 1;26(15):3505-12
– reference: 22217937 - Nature. 2012 Jan 19;481(7381):389-93
– reference: 11818203 - Eur J Cancer. 2002 Feb;38(3):380-6
– reference: 16809442 - Endocrinology. 2006 Oct;147(10):4831-42
SSID ssj0009087
Score 2.2384803
Snippet Background: The expression of oestrogen receptor (ER) α characterises a subset of breast cancers associated with good response to endocrine therapy. However,...
The expression of oestrogen receptor (ER) α characterises a subset of breast cancers associated with good response to endocrine therapy. However, the clinical...
SourceID swepub
pubmedcentral
proquest
pubmed
pascalfrancis
crossref
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 918
SubjectTerms 692/53/2423
692/699/67/1347
692/699/67/322
692/700/565/1331/238
Adult
Aged
Aged, 80 and over
Biological and medical sciences
Biomedical and Life Sciences
Biomedicine
Breast Neoplasms - metabolism
Breast Neoplasms - pathology
Cancer Research
Drug Resistance
Epidemiology
Estrogen Receptor beta - metabolism
Female
Gynecology. Andrology. Obstetrics
Humans
Lymph Nodes - metabolism
Lymph Nodes - pathology
Lymphatic Metastasis - pathology
Mammary gland diseases
Medical sciences
Middle Aged
Molecular Diagnostics
Molecular Medicine
Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
Oncology
Prognosis
Tumors
Young Adult
Title Oestrogen receptors β1 and βcx have divergent roles in breast cancer survival and lymph node metastasis
URI https://link.springer.com/article/10.1038/bjc.2014.398
https://www.ncbi.nlm.nih.gov/pubmed/25025959
https://www.proquest.com/docview/1558521781
https://pubmed.ncbi.nlm.nih.gov/PMC4150283
http://kipublications.ki.se/Default.aspx?queryparsed=id:129681837
Volume 111
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Zi9RAEC72ABFEvI3H0ILuiwaTPpLOow67LMKuIi7MW-h0KuzomhkmM6J_yx_ib7IqxyxRF3xJQlLdOaq6-uvuylcAz2WclM5HJkySKgupP1ahUzINI5lhVhVIvSJPDZycJsdn-t3MzHbg1fAvTBu031Jatm56iA57XXxmvsFY0xjd7sI-k7bzUGuaTC8pdiPbMWTy5Fsmoz7MPVJ2VHrUAd1Yuoa-RdUlsfgXyvw7WHK7YvoHu2jbIx3dgps9lBRvuoe_DTtY34FrJ_1i-V2Yv6c7rBZkIYLcGi45r4749TMWri5p77-Lc_cNRcmRGfyDleBIw0bMa1FwpPpaeLaIlWg25E7IINtyFz9I_aJelCi-4pqkXDNv7sHZ0eGn6XHYZ1YIvVbUNNDr0umkssYb5Z1xkoCWUdrrivGbsQpLrFBhhEXkq4RAm6_It8XOqZKT09-HvXpR40MQiLFxcaGztJTamahIvIvioogMVpmTPoCXw-fOfU87ztkvLvJ2-VvZnJSTs3JyUk4AL7bSy45u4wq5yUhzW2EaAKZSpzKAZ4Mqc2owvArialxsmpwAlCXMkto4gAedai9LG4KAmckCSEdK3wowGff4Sj0_b0m5CQgxVAvgYDCPvPcGzRVvcNAZz6ju_tQXOsLc8MSUffS_NT6G63zIE94yeQJ769UGnxJiWhcT2E1nKW3tNJ7A_tvD0w8fJ23j-Q00axqa
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3bbtNAEB2VIgESQtwxl7JItC_I6novvjzwgAJVSpvy0kp9W9brsRooThQnQP-Fr-BD-CZmbSeVgUq89CmRM94ke2Z2z-6OzwC8FFFcWMd1GMdlFtJ8LEMrRRJykWFW5kizot8aGB3EwyP1_lgfr8GP5bMwTdJ-I2nZDNPL7LDt_JPXG4wUrdHTLoVyD8--0QKtfr37ltDcFGLn3eFgGHY1BEKnJDkBOlVYFZepdlo6q60gSqGlcqr0TEWnEgssUSLHnLsyJnriSoriyFpZ-DLs1O4VuEqsPvYxM4gH55K-PG0VOf1mXyZ4l1bPZdr7tb0J7-bU1tT3ZVs041-s9u_kzNUJ7R9qps0MuHMbbnXUlb1pO-sOrGF1F66NusP5ezD-QN8wm5BHMhpGcerr-LBfPyNmq4Je3Xd2Yr8iK3wmiH-gi_nMxpqNK5b7zPg5c94DZ6xe0PBFAdDcd3pG7saqSYHsC87Jytbj-j4cXQoKD2C9mlT4CBhipG2UqywphLKa57GzPMpzrrHMrHABvFp2t3GdzLmvtnFqmuN2mRoCx3hwDIETwObKetrKe1xgt9FDbmVMC85EqEQE8GIJpaEA9acutsLJojZE2FLiSEkaBfCwhfb8bk2UM9NZAEkP9JWBF__uf1KNTxoRcCJenhoGsLV0D9ONPvUF_2CrdZ5e292lz_QOjfYbYenj_23xOVwfHo72zf7uwd4TuOEv-812ET-F9flsgc-Irc3zjSZoGHy87Cj9DU2_VDk
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3dbtMwFD4aQ5qQEOKf8DOMxHaDAo5j5-eCC9RRbYwNLpi0O-M4x1rZllZNC-xteAYehGfiOEk7BZjEza5apSdu6-8c-7N98h2A5yJKSmO5CpPE5SHNx3FoYpGGXOSYuwJpVvRbA3v7yfaBfHeoDlfgx-JZmCZpv5G0bIbpRXbYq-KL1xuMJK3Rs5eT0nVplLt49o0WafXrnS1CdEOI4dtPg-2wqyMQWhmTI6CVpZGJy5RVsTXKCKIVKpZWOs9WVBZjiQ5j5Fhw6xKiKNZRJEfGxKUvxU7tXoGrxOy5TxobJINzWV-etaqcfsMvF7xLredx1vvFvUnv-sTU1P-uLZzxL2b7d4Lm8pT2D0XTZhYc3oQbHX1lb9oOuwUrWN2Gtb3ugP4OjD7QN0zH5JWMhlKc-Fo-7NfPiJmqpFf7nR2Zr8hKnw3iH-piPruxZqOKFT47fsas98Ipq-c0hFEQNPednJHLsWpcIjvFGVmZelTfhYNLQeEerFbjCh8AQ4yUiQqZp6WQRvEisYZHRcEVutwIG8CLRXdr20md-4obJ7o5co8zTeBoD44mcALYWFpPWomPC-zWe8gtjWnRmQqZigCeLaDUFKT-5MVUOJ7XmkhbRjwpzaIA7rfQnt-tiHbmKg8g7YG-NPAC4P1PqtFRIwRO5MvTwwA2F-6huxGovuAfbLbO02u7u3RM71ArvxmWPfzfFp_C2setoX6_s7_7CK75q36_XSSPYXU2neMTImyzYr2JGQafLztIfwMRNFVC
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Oestrogen+receptors+%CE%B21+and+%CE%B2cx+have+divergent+roles+in+breast+cancer+survival+and+lymph+node+metastasis&rft.jtitle=British+journal+of+cancer&rft.au=Rosin%2C+G&rft.au=de%2C+Boniface+J&rft.au=Karthik%2C+GM&rft.au=Frisell%2C+J&rft.date=2014-08-26&rft.issn=0007-0920&rft.volume=111&rft.issue=5&rft.spage=918&rft_id=info:doi/10.1038%2Fbjc.2014.398&rft.externalDocID=oai_swepub_ki_se_520278
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-0920&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-0920&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-0920&client=summon